Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Korea-based Dong-A Pharmaceutical has signed MOU with Incheon Free Economic Zone to develop biopharmaceutical industry complex including biosimilar production plant in Songdo International Business District, South Korea.
Subscribe to our email newsletter
The facility is intended to target the global markets with antibody based drugs including Herceptin biosimilar.
Dong-A and Japanese company, Meiji Seika Pharma signed an agreement to develop biosimilar prodcuts.
Dong-A and Meiji will first construct a biosimilar cGMP plant in the Songdo International Business District, and add on facilities to conduct research, develop, manufacture and commercialize biosimilar products in global markets.
Dong-A also plans additional investment in Songdo to export biopharmaceutical products such as PEG-G-CSF for neutropenia, interferon beta, and diabetes treatments in Dong-A’s current pipeline.